Cargando…

Advances in mRNA and other vaccines against MERS-CoV

Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic human coronavirus (CoV). Belonging to the same beta-CoV genus as severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and SARS-CoV-2, MERS-CoV has a significantly higher fatality rate with limited human-to-human t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tai, Wanbo, Zhang, Xiujuan, Yang, Yang, Zhu, Jiang, Du, Lanying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Inc. 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603276/ https://www.ncbi.nlm.nih.gov/pubmed/34801748 http://dx.doi.org/10.1016/j.trsl.2021.11.007

Ejemplares similares

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
por: Shi, Juan, et al.
Publicado: (2022)

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
por: Zhou, Yusen, et al.
Publicado: (2019)

Current advancements and potential strategies in the development of MERS-CoV vaccines
por: Zhang, Naru, et al.
Publicado: (2014)

Receptor-binding domain-based subunit vaccines against MERS-CoV
por: Zhang, Naru, et al.
Publicado: (2015)

The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation
por: George, Parakkal Jovvian, et al.
Publicado: (2020)

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2016)

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2018)

mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern
por: Wang, Gang, et al.
Publicado: (2022)

A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
por: Shi, Juan, et al.
Publicado: (2022)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines
por: Du, Lanying, et al.
Publicado: (2016)

A chimeric MERS-CoV virus-like particle vaccine protects mice against MERS-CoV challenge
por: Park, Jung-Eun, et al.
Publicado: (2022)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
por: Jiang, Shibo, et al.
Publicado: (2020)

An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants
por: Tai, Wanbo, et al.
Publicado: (2023)

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
por: Liu, William J., et al.
Publicado: (2017)

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2013)

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2022)

Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain
por: He, Lei, et al.
Publicado: (2019)

Potential Immunogenic Activity of Computationally Designed mRNA- and Peptide-Based Prophylactic Vaccines against MERS, SARS-CoV, and SARS-CoV-2: A Reverse Vaccinology Approach
por: Khan, Taimoor, et al.
Publicado: (2022)

Evaluation of candidate vaccine approaches for MERS-CoV
por: Wang, Lingshu, et al.
Publicado: (2015)

MERS-CoV
por: Müller, Marcel A
Publicado: (2014)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
por: Abdelghany, T.M., et al.
Publicado: (2021)

Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread
por: Lu, Lu, et al.
Publicado: (2013)

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
por: Jackson, Lisa A., et al.
Publicado: (2020)

Symptomology following mRNA vaccination against SARS-CoV-2
por: Ebinger, Joseph E., et al.
Publicado: (2021)

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
por: Echaide, Miriam, et al.
Publicado: (2023)

The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
por: Jamous, Yahya F, et al.
Publicado: (2023)

Vaccination strategies for mitigation of MERS-CoV outbreaks
por: Bosaeed, Mohammad, et al.
Publicado: (2023)

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
por: Ma, Cuiqing, et al.
Publicado: (2014)

A novel mRNA vaccine, SYS6006, against SARS-CoV-2
por: Xu, Ke, et al.
Publicado: (2023)

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
por: Tai, Wanbo, et al.
Publicado: (2020)

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection
por: Channappanavar, Rudragouda, et al.
Publicado: (2015)

Camels, MERS-CoV, and other emerging infections in east Africa
por: Roess, Amira, et al.
Publicado: (2016)

Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen
por: Nyon, Mun Peak, et al.
Publicado: (2018)

Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction
por: Cao, Wenpeng, et al.
Publicado: (2021)

Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
por: Cho, Hansam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gdsn171ob8vbkikvjvlptghjeq